Get the Stockscreener App
8.85
0.11%
0.010
Valneva Se Adr stock is traded at $8.85, with a volume of 35,793.
It is up +0.11% in the last 24 hours and up +14.05% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$8.84
Open:
$8.94
24h Volume:
35,793
Relative Volume:
0.57
Market Cap:
$753.08M
Revenue:
$163.13M
Net Income/Loss:
$-34.75M
P/E Ratio:
-17.18
EPS:
-0.5152
Net Cash Flow:
$-231.66M
1W Performance:
-23.97%
1M Performance:
+14.05%
6M Performance:
+24.30%
1Y Performance:
+20.57%
1-Day Range:
$8.7332
$8.9868
1-Week Range:
$8.71
$9.50
52-Week Range:
$3.62
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
8.85 | 751.68M | 163.13M | -34.75M | -231.66M | -0.5152 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Resumed | H.C. Wainwright | Buy |
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ - MSN
Valneva selloff on FDA suspension overdone, says H.C. Wainwright - MSN
Valneva SE ADR: Rising -26.86% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Valneva price target lowered to $14 from $18 at Jefferies - MSN
Jefferies lowers Valneva stock price target to $14 on FDA suspension - Investing.com
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine By Investing.com - Investing.com South Africa
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine - Investing.com
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. - GlobeNewswire Inc.
Valneva (NASDAQ:VALN) Shares Gap Up – Still a Buy? - Defense World
HC Wainwright Estimates Valneva’s Q3 Earnings (NASDAQ:VALN) - Defense World
Valneva (NASDAQ:VALN) Coverage Initiated by Analysts at HC Wainwright - Defense World
Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 91.2% - Defense World
Valneva (NASDAQ:VALN) Trading Up 14.3% After Better-Than-Expected Earnings - Defense World
Valneva (NASDAQ:VALN) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Valneva SE earnings beat by $0.22, revenue topped estimates - Investing.com
Valneva (NASDAQ:VALN) Trading Down 6.7% – Here’s What Happened - Defense World
Valneva (NASDAQ:VALN) Sets New 1-Year High – Still a Buy? - Defense World
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock? - Yahoo Finance
[Valneva SE] Declaration of shares and voting rights - GlobeNewswire Inc.
Valneva SE earnings missed by $0.01, revenue topped estimates - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - Louisiana First News
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
Valneva SE Company Investigated by the Portnoy Law Firm - GlobeNewswire
Valneva shares leap on Brazilian approval of chikungunya vaccine By Investing.com - Investing.com India
Valneva shares leap on Brazilian approval of chikungunya vaccine - Investing.com Australia
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
VALN Doses First Infant With Shigella Vaccine In Mid-Stage Study - Barchart.com
H.C. Wainwright maintains Buy on Valneva with $17 price target - Investing.com
Valneva SE ADR’s Banking’s 100-Day Moving Average at 5.61: Will the Stock Break Through? - investchronicle.com
The Schall Law Probes Valneva Over Vaccine Safety Concerns - Lawyer Monthly
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - Business Wire
Valneva SE earnings missed by $0.32, revenue fell short of estimates - Investing.com India
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):